135 related articles for article (PubMed ID: 28545688)
1. Quinacrine in endometrial cancer: Repurposing an old antimalarial drug.
Kalogera E; Roy D; Khurana A; Mondal S; Weaver AL; He X; Dowdy SC; Shridhar V
Gynecol Oncol; 2017 Jul; 146(1):187-195. PubMed ID: 28545688
[TBL] [Abstract][Full Text] [Related]
2. Quinacrine promotes autophagic cell death and chemosensitivity in ovarian cancer and attenuates tumor growth.
Khurana A; Roy D; Kalogera E; Mondal S; Wen X; He X; Dowdy S; Shridhar V
Oncotarget; 2015 Nov; 6(34):36354-69. PubMed ID: 26497553
[TBL] [Abstract][Full Text] [Related]
3. Novel applications for an established antimalarial drug: tumoricidal activity of quinacrine.
Yan H; Bian A; Gao X; Li H; Chen Z; Liu X
Future Oncol; 2018 Jun; 14(15):1511-1520. PubMed ID: 29380639
[TBL] [Abstract][Full Text] [Related]
4. A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth.
Marchion DC; Bicaku E; Xiong Y; Bou Zgheib N; Al Sawah E; Stickles XB; Judson PL; Lopez AS; Cubitt CL; Gonzalez-Bosquet J; Wenham RM; Apte SM; Berglund A; Lancaster JM
Oncol Rep; 2013 May; 29(5):2011-8. PubMed ID: 23467907
[TBL] [Abstract][Full Text] [Related]
5. In vitro sensitivity of human endometrial cancer cell lines to paclitaxel or irinotecan (CPT-11) in combination with other aniticancer drugs.
Hiramatsu HP; Kikuchi Y; Seto H; Nagata I
Anticancer Drugs; 2000 Aug; 11(7):573-8. PubMed ID: 11036961
[TBL] [Abstract][Full Text] [Related]
6. Potentiation of platinum antitumor effects in human lung tumor xenografts by the angiogenesis inhibitor squalamine: effects on tumor neovascularization.
Schiller JH; Bittner G
Clin Cancer Res; 1999 Dec; 5(12):4287-94. PubMed ID: 10632372
[TBL] [Abstract][Full Text] [Related]
7. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
Witham J; Valenti MR; De-Haven-Brandon AK; Vidot S; Eccles SA; Kaye SB; Richardson A
Clin Cancer Res; 2007 Dec; 13(23):7191-8. PubMed ID: 18056200
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel, Carboplatin and 1,25-D3 Inhibit Proliferation of Endometrial Cancer Cells
Kuittinen T; Rovio P; Staff S; Luukkaala T; Kallioniemi A; Grénman S; Laurila M; Mäenpää J
Anticancer Res; 2017 Dec; 37(12):6575-6581. PubMed ID: 29187432
[TBL] [Abstract][Full Text] [Related]
9. Impact of carboplatin plus paclitaxel combined with endostar against A375 melanoma cells: An in vitro and in vivo analysis.
Zheng AW; Jia DD; Xia LM; Jin G; Wu H; Li T
Biomed Pharmacother; 2016 Oct; 83():1321-1326. PubMed ID: 27571875
[TBL] [Abstract][Full Text] [Related]
10. Rational combination therapy of vintafolide (EC145) with commonly used chemotherapeutic drugs.
Reddy JA; Dorton R; Bloomfield A; Nelson M; Vetzel M; Guan J; Leamon CP
Clin Cancer Res; 2014 Apr; 20(8):2104-14. PubMed ID: 24429878
[TBL] [Abstract][Full Text] [Related]
11. Endometrial Cancers Harboring Mutated Fibroblast Growth Factor Receptor 2 Protein Are Successfully Treated With a New Small Tyrosine Kinase Inhibitor in an Orthotopic Mouse Model.
Taurin S; Yang CH; Reyes M; Cho S; Coombs DM; Jarboe EA; Werner TL; Peterson CM; Janát-Amsbury MM
Int J Gynecol Cancer; 2018 Jan; 28(1):152-160. PubMed ID: 28953502
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of paclitaxel activity against hormone-refractory prostate cancer cells in vitro and in vivo by quinacrine.
de Souza PL; Castillo M; Myers CE
Br J Cancer; 1997; 75(11):1593-600. PubMed ID: 9184173
[TBL] [Abstract][Full Text] [Related]
13. Augmented growth inhibition of B16-BL6 melanoma by combined treatment with a selective matrix metalloproteinase inhibitor, MMI-166, and cytotoxic agents.
Hojo K; Maki H; Sawada TY; Maekawa R; Yoshioka T
Anticancer Res; 2002; 22(6A):3253-9. PubMed ID: 12530072
[TBL] [Abstract][Full Text] [Related]
14. The synergistic cytotoxicity of cisplatin and taxol in killing oral squamous cell carcinoma.
Huang GC; Liu SY; Lin MH; Kuo YY; Liu YC
Jpn J Clin Oncol; 2004 Sep; 34(9):499-504. PubMed ID: 15466821
[TBL] [Abstract][Full Text] [Related]
15. Quinacrine and curcumin synergistically increased the breast cancer stem cells death by inhibiting ABCG2 and modulating DNA damage repair pathway.
Nayak D; Tripathi N; Kathuria D; Siddharth S; Nayak A; Bharatam PV; Kundu C
Int J Biochem Cell Biol; 2020 Feb; 119():105682. PubMed ID: 31877386
[TBL] [Abstract][Full Text] [Related]
16. Navitoclax augments the activity of carboplatin and paclitaxel combinations in ovarian cancer cells.
Stamelos VA; Robinson E; Redman CW; Richardson A
Gynecol Oncol; 2013 Feb; 128(2):377-82. PubMed ID: 23168176
[TBL] [Abstract][Full Text] [Related]
17. Anti-tumor effect of inhibition of IL-6 signaling in mucoepidermoid carcinoma.
Mochizuki D; Adams A; Warner KA; Zhang Z; Pearson AT; Misawa K; McLean SA; Wolf GT; Nör JE
Oncotarget; 2015 Sep; 6(26):22822-35. PubMed ID: 26287605
[TBL] [Abstract][Full Text] [Related]
18. In vitro responses of ovarian cancers to platinums and taxanes.
Kornblith P; Wells A; Gabrin MJ; Piwowar J; Chattopadhyay A; George LD; Ochs RL; Burholt D
Anticancer Res; 2003; 23(1B):543-8. PubMed ID: 12680143
[TBL] [Abstract][Full Text] [Related]
19. Consequences of telomerase inhibition and combination treatments for the proliferation of cancer cells.
Chen Z; Koeneman KS; Corey DR
Cancer Res; 2003 Sep; 63(18):5917-25. PubMed ID: 14522918
[TBL] [Abstract][Full Text] [Related]
20. Down-regulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo.
Spänkuch B; Heim S; Kurunci-Csacsko E; Lindenau C; Yuan J; Kaufmann M; Strebhardt K
Cancer Res; 2006 Jun; 66(11):5836-46. PubMed ID: 16740723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
